TOPLINE:

TNF inhibitors were used by 64% of pregnant women with inflammatory diseases through all trimesters. Those with continuous use through all trimesters had reduced use of corticosteroids postpartum.

METHODOLOGY:

Researchers analyzed prescriptions of TNF inhibitors in pregnant women with chronic inflammatory diseases in the MarketScan US commercial claims database, focusing on usage patterns and discontinuation compared with those who continued using them throughout pregnancy.

They included live birth pregnancies among women aged 15-45 years with rheumatoid arthritis, radiographic axial spondyloarthritis, psoriatic arthritis, psoriasis, and/or inflammatory bowel disease who were hospitalized between 2011 and 2021.

A total of 3711 pregnancies were exposed to TNF inhibitors during

See Full Page